Check for updates

OPEN ACCESS

EDITED BY Malgorzata Ziarno, Warsaw University of Life Sciences, Poland

REVIEWED BY Haihua Ruan, Tianjin University of Commerce, China Zhongming Wu, Shandong Provincial Hospital Affiliated to Shandong First Medical University, China Ilkka Rautiainen, University of Jyväskylä, Finland

*CORRESPONDENCE Baocheng Chang ⊠ changbc1970@126.com Juhong Yang ⊠ megii0315@126.com Jianjun Qiao ⊠ jianjunq@tju.edu.cn

[†]These authors share first authorship

RECEIVED 30 August 2024 ACCEPTED 05 December 2024 PUBLISHED 05 February 2025

CITATION

Wu H, Li Y, Jiang Y, Li X, Wang S, Zhao C, Yang X, Chang B, Yang J and Qiao J (2025) Machine learning prediction of obesity-associated gut microbiota: identifying *Bifidobacterium pseudocatenulatum* as a potential therapeutic target. *Front. Microbiol.* 15:1488656. doi: 10.3389/fmicb.2024.1488656

COPYRIGHT

© 2025 Wu, Li, Jiang, Li, Wang, Zhao, Yang, Chang, Yang and Qiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Machine learning prediction of obesity-associated gut microbiota: identifying *Bifidobacterium pseudocatenulatum* as a potential therapeutic target

Hao Wu^{1†}, Yuan Li^{2†}, Yuxuan Jiang^{3†}, Xinran Li², Shenglan Wang², Changle Zhao^{1,4}, Ximiao Yang¹, Baocheng Chang^{2*}, Juhong Yang^{2,5*} and Jianjun Qiao^{1,4*}

¹Zhejiang Institute of Tianjin University (Shaoxing), Shaoxing, China, ²NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin, China, ³Yidu Cloud (Beijing) Technology Co., Ltd., Beijing, China, ⁴Department of Pharmaceutical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin, China, ⁵Guangdong Medical University, Zhanjiang, China

Background: The rising prevalence of obesity and related metabolic disorders highlights the urgent need for innovative research approaches. Utilizing machine learning (ML) algorithms to predict obesity-associated gut microbiota and validating their efficacy with specific bacterial strains could significantly enhance obesity management strategies.

Methods: We leveraged gut microbiome data from 1,563 healthy individuals and 2,043 overweight patients sourced from the GMrepo database. We assessed the anti-obesity effects of *Bifidobacterium pseudocatenulatum* through experimentation with *Caenorhabditis elegans* and C3H10T1/2 cells.

Results: Our analysis revealed a significant correlation between gut bacterial composition and body weight. The top 40 bacterial species were utilized to develop ML models, with XGBoost demonstrating the highest predictive accuracy. SHAP analysis indicated a negative association between the relative abundance of six bacterial species, including *B. pseudocatenulatum*, and body mass index (BMI). Furthermore, *B. pseudocatenulatum* was shown to reduce lipid accumulation in *C. elegans* and inhibit lipid differentiation in C3H10T1/2 cells.

Conclusion: *Bifidobacterium pseudocatenulatum* holds potential as a therapeutic agent for managing diet-induced obesity, underscoring its relevance in microbiome-based obesity research and intervention.

KEYWORDS

overweight, machine learning, XGBoost-SHAP, intestinal microbiota, *Bifidobacterium* pseudocatenularis

Introduction

Overweight and obesity are major global public health challenges, presenting substantial clinical difficulties (Laine and Wee, 2023). Obesity is a key precursor to various widespread diseases, including type 2 diabetes, hypertension, non-alcoholic fatty liver disease, cancer, and obstructive sleep apnea syndrome (Tsai and Bessesen, 2019; Quek et al., 2023). Despite numerous efforts aimed at treatment, mitigation, and prevention, the global prevalence and severity of obesity continue to rise (Heindel et al., 2024). Etiologically, obesity is a complex condition driven primarily by the interplay of genetic and environmental factors (Laine and Wee, 2023). As a result, effective obesity treatment requires a multidisciplinary approach (Velazquez and Apovian, 2018), highlighting the urgent need for innovative prevention and therapeutic strategies.

The gut microbiota plays a crucial role in the digestion, absorption, and metabolism of food, influencing body weight through the regulation of metabolism, appetite, bile acid metabolism, and the endocrine, nervous, and immune systems (Van Hul and Cani, 2023). Studies by Cho et al. (2012) and Cox et al. (2014) demonstrated that subtherapeutic doses of antibiotics in mice lead to increased weight and fat mass, underscoring the gut microbiota's role in the etiology of obesity. Backhed et al. (2004) further showed that gut microbiota directly participate in host energy metabolism; colonizing germ-free mice with gut microbiota increases blood glucose and insulin levels while promoting lipid storage in adipose tissue. Research also indicates that omega-3 fatty acids protect against mild inflammation, metabolic endotoxemia, insulin resistance, and obesity. Probiotics such as Bifidobacterium, Lactobacillus, and Akkermansia muciniphila have been associated with the beneficial effects of omega-3 (Carvalho et al., 2012). Although there is no conclusive evidence that specific microbes are the primary cause of obesity or overweight issues, the role of gut microbiota in metabolic disorders and obesity has been consistently demonstrated (Liang et al., 2023). Notably, various probiotic strains have been shown to effectively reduce BMI (Tome-Castro et al., 2021), with significant research focusing on Lactobacillus, Bifidobacterium, and Akkermansia muciniphila, which can improve obesity, blood glucose levels, and insulin resistance (Koutnikova et al., 2019; Qiu et al., 2022; Dao et al., 2016). Thus, the targeted study of gut microbiota as early indicators and preventive measures for obesity, along with the development of probiotics with potential anti-obesity effects, is vital for effective obesity management.

Given the numerous interfering factors and significant challenges in detecting gut microbiota, the lack of objective and large-scale clinical data is likely a key reason why gut microbiota have struggled to predict overweight and obesity. In this context, machine learning (ML) offers a promising approach by classifying the gut microbiota of normal and overweight populations based on extensive clinical datasets. ML algorithms, rather than solving inference problems or understanding the relationships between variables, learn directly from data, identifying complex nonlinear patterns to make accurate predictions (Deo, 2015). By exploring disease risk through ML, we can obtain quick, real-time, and interpretable results regarding risk factors and conditions (Safaei et al., 2021). Therefore, this study aims to use feature selection methods to characterize the gut microbiota landscape, develop and validate ML algorithms to identify overweight individuals, and apply interpretability techniques to visualize predictive factors. Additionally, by leveraging ML methods to discover potential probiotics, we validate the anti-obesity effects of specific strains through nematode and cell experiments, offering a new perspective for probiotic development.

Materials and methods

Data sources and processing

The human gut microbiota data for this study were obtained from the GMrepo database,1 including individuals aged 18 years and older classified as either healthy or overweight. Overweight was defined as BMI \geq 25, encompassing individuals with BMI \geq 30 (commonly classified as obese). To ensure homogeneity, samples from individuals with other underlying diseases were excluded, and participants were categorized into two groups: overweight (BMI ≥25) and control (BMI <25). Stratified sampling was applied to the overweight group to minimize biases related to age and gender distribution, resulting in 3,606 samples analyzed (2,043 overweight and 1,563 control). The inclusion of individuals with obesity under the overweight category is discussed as a potential limitation. Data were imported into Python using pandas, enabling operations like filtering, alignment, and transformation. Missing values for bacterial relative abundance and gender were replaced with zeros to ensure data integrity. Z-score normalization was applied within cross-validation to avoid data leakage by calculating normalization parameters only on the training data and applying them to the test data. Samples with low sequencing coverage (<1%) were excluded, and potential contaminants were identified and removed through background sample comparisons, ensuring a robust and high-quality dataset.

Microbiota diversity indices

We calculated the Shannon index and Chao1 index to assess the diversity of gut microbiota among the study groups. The Shannon index provides insights into the richness and evenness of microbial communities, while the Chao1 index estimates species richness based on the number of observed species and their frequency.

Statistical analysis and visualization

To visualize the microbial diversity and community structure, we generated heatmaps and boxplots. Heatmaps illustrate the relative abundance of microbial taxa across samples, highlighting patterns of similarity and differences between groups. Boxplots provide a comparative overview of diversity indices between the overweight and control groups, facilitating the identification of significant differences.

Data standardization

In this study, we applied *z*-score standardization to all input features to ensure that the features were on the same scale for

¹ https://gmrepo.humangut.info

comparison. The standardization was performed before model training to eliminate differences in scale between features, preventing certain features from disproportionately influencing the model results due to their different units. All numerical data (such as microbial community relative abundance and sample information) were standardized before being input into the machine learning models. This step helped improve the model's stability and ensured that all features had equal weight during model training.

Model construction and evaluation

To investigate the potential of gut microbiota dysbiosis as biomarkers for overweight, we developed machine learning models using XGBoost, support vector machine (SVM), logistic regression, and decision tree algorithms. The optimization target for model performance was AUC (area under the ROC curve), though additional metrics such as accuracy, precision, recall, and F_1 -score were also assessed. For each algorithm, we used the following settings: In XGBoost, hyperparameter optimization was performed using GridSearchCV, exploring the ranges of colsample_bytree: [0.8, 0.9, 1.0], gamma: [0, 0.1, 0.2], learning_rate (eta): [0.01, 0.1, 0.2], max_depth: [3, 4, 5], n_estimators: [50, 100, 150], and subsample: [0.8, 0.9, 1.0]. A 5-fold cross-validation strategy was employed to prevent overfitting and ensure robust model performance. For SVM (support vector machine), the radial basis function (RBF) kernel was used, and hyperparameters such as C (regularization parameter) and gamma (kernel coefficient) were optimized using a grid search. The values tested for C ranged from 1 to 100, and gamma ranged from 0.001 to 0.1. In Logistic Regression, default parameters were used, with the main hyperparameter being the regularization parameter C, which was optimized using GridSearchCV with values from 0.01 to 10. For the Decision Tree model, the default max_depth parameter was used, and different values for min_samples_split (ranging from 2 to 10) and min_samples_leaf (ranging from 1 to 4) were explored to control tree growth and avoid overfitting. After comparing performance metrics, including AUC, we determined that XGBoost was the most effective model for predicting overweight status based on gut microbiota data.

SHAP-based model interpretability analysis

To interpret the XGBoost model's predictions, we employed SHAP (Shapley Additive Explanations), an approach grounded in game theory (Li et al., 2023). SHAP quantifies the contribution of each feature to the model's output by assigning a Shapley value that indicates the direction and magnitude of each feature's impact. Positive SHAP values (>0) suggest a positive influence on the prediction, while negative SHAP values (<0) indicate a negative influence (Song et al., 2023). SHAP provides both global and local insights: Global Interpretation calculates the average SHAP value of each feature across all samples, highlighting overall feature importance, while local interpretation assesses each feature's impact on individual predictions. The SHAP framework enabled us to generate "SHAP Summary Plots," visualizing feature importance and contributing to a deeper understanding of the influence of gut microbiota features on overweight classification.

Bacterial culture and co-culture experiments

We cultured *B. pseudocatenulatum* strains (JXL-01, JXL-02, JXL-03, and JXL-05) anaerobically in MRS medium (Shanghai Macklin Biochemical Technology Co., Ltd.) at 37° C for 24 h. Once the bacterial concentration reached 10^{9} CFU/mL, the culture was centrifuged at 7,000 rpm for 15 min. The supernatant was discarded, and the bacterial pellet was washed several times with sterile PBS. The bacteria were then resuspended in complete DMEM medium and incubated anaerobically at 37° C for an additional 2 h. The supernatant was collected for subsequent cell experiments.

Synchronization of Caenorhabditis elegans

L4-stage *C. elegans* were collected in a centrifuge tube, and 1 mL of M9 buffer was added to wash away excess *E. coli* OP50. After allowing the worms to settle, the supernatant was removed, and this washing step was repeated three times. Next, 1 mL of lysis solution was added and thoroughly mixed. After discarding the supernatant, the worms were washed three times with M9 buffer via centrifugation (3,000 rpm, 1 min), retaining the eggs. The eggs were then transferred to new NGM plates and incubated at 20°C in a biochemical incubator. After approximately 16–18 h, the eggs developed into L1-stage larvae.

Culture of *Caenorhabditis elegans* and fat measurement

B. pseudocatenulatum strains (JXL-01, JXL-02, JXL-03, and JXL-05) and E. coli OP50 were cultured in liquid medium until reaching the logarithmic phase. After centrifugation at 8,000 rpm for 10 min at 4°C, the bacterial pellets of B. pseudocatenulatum were collected and resuspended in M9 buffer to an OD of 0.5. A total of $100 \,\mu\text{L}$ of the bacterial suspension was then applied to 60 mm NGM solid plates containing the worm eggs and incubated at 20°C. After approximately 3 to 4 days, the worms developed into L4-stage larvae, with E. coli OP50 serving as a control group. Following an additional 3 days of continued culture with the bacterial suspension, 20 randomly selected worms were subjected to Oil Red O staining to measure fat accumulation. The worms were rinsed three times with M9 buffer, anesthetized with 25 mM levamisole hydrochloride, and treated with 200 µL of 4% paraformaldehyde solution for 20 min. The solution was removed, and the worms underwent three freeze-thaw cycles using liquid nitrogen. Subsequently, the worms were stained with 60% isopropanol and Oil Red O solution for 5 h. Excess dye was rinsed off with M9 buffer, and the staining was observed under an optical microscope to analyze fat content.

Culture and differentiation of C3H10 into adipocytes

Mouse mesenchymal stem cells (C3H10 cells) were generously provided by Professor En-Dong Zhu's research group at the Endocrinology Institute of Tianjin Medical University. The cells were cultured in DMEM medium (Gibco, United States) at 37°C, supplemented with 10% fetal bovine serum (FBS) (Hyclone,

United States) and 100 U/mL penicillin/streptomycin (Beijing ZSbio). They were divided into two groups: a control group and a B. pseudocatenulatum metabolite intervention group (B.p), with the intervention lasting for 24 h. Following this, the cells were treated with specific differentiation media to induce differentiation into adipocytes. Differentiation Induction Agent A, consisting of DMEM high-glucose complete medium supplemented with 0.2 µg/mL dexamethasone, 5 µg/mL insulin, 100 µM indomethacin, and 250 µM IBMX, was applied for 3 days. This was followed by Differentiation Induction Agent B, which included DMEM high-glucose complete medium with 5 µg/mL insulin, administered for an additional 3 days. This differentiation process ensured that C3H10 cells functionally mimic adipose tissue, making them suitable for subsequent fat accumulation studies. For co-culture experiments, we used 10% of the metabolites from the bacterial cultures, ensuring that the conditions for cell differentiation were consistent across all experiments.

Cell viability

Cell viability was assessed using the CCK-8 Cell Counting Kit (Shanghai Taosu Bio Technology Co., Ltd.) according to the manufacturer's instructions. C3H10 cells were seeded in a 96-well plate with 100 μ L of cell suspension per well and incubated at 37°C with various concentrations of *B. pseudocatenulatum* for 24 h. Following treatment, 10 μ L of CCK-8 reagent was added to each well and incubated for an additional 30 min. Absorbance at 450 nm was then measured using a multifunctional microplate reader (Thermo Fisher Scientific), and cell viability percentages were calculated for each concentration.

Oil Red O staining and lipid droplet analysis

Oil Red O staining was performed, and lipid droplets were analyzed using cell imaging. The procedure followed the Oil Red O kit instructions (Beijing Solarbio Science & Technology Co., Ltd.). First, Solution A and Solution B were mixed in a 3:2 ratio to prepare the staining solution. Cells were fixed with ORO fixative for 25 min, followed by staining with freshly prepared Oil Red O solution for the recommended time. After staining, cells were washed to remove excess dye, and the cell nuclei were counterstained with Mayer's Hematoxylin, followed by washing with distilled water. Finally, the cells were treated with ORO buffer for 1 min and observed under a microscope to analyze the lipid droplets.

Quantitative reverse-transcription PCR

Total RNA was purified from cells using the Total RNA Extraction Kit (Tiangen Biotech Co., Ltd.) according to the manufacturer's instructions. After quantifying the RNA concentration and purity, 1 µg of RNA was reverse transcribed using the M-MuLV First Strand cDNA Synthesis Kit (Tiangen Biotech). The resulting cDNA was then amplified on a PCR cycler (Eppendorf, Germany) using the SYBR Green Real-Time PCR Kit (Tiangen Biotech). Relative mRNA levels were determined using the $2^{-\Delta\Delta C_{T}}$ method, with GAPDH mRNA serving as the reference. The primer sequences used in the study are shown in the Supplementary Table S1.

Statistical analysis

Statistical analysis in this study was conducted using several methods. ML analysis was performed using Python (version 3.10.2), while the Mann–Whitney U test was applied for non-parametric data, with *p*-values adjusted using the Bonferroni method and a significance level set at p < 0.01. Experimental data were analyzed using SPSS (version 25.0). Data normality was assessed, and for normally distributed data, independent samples *t*-tests were used to compare two groups. Results were expressed as mean \pm standard deviation (SD), with a *p*-value of p < 0.05 considered statistically significant. Data processing for image analysis was carried out using Fiji ImageJ. These methods ensured rigorous and accurate data analysis, providing reliable and meaningful results for the study.

Results

Data processing results

From the GMrepo database, a total of 14,028 samples containing human gut microbiome information were downloaded. After sample screening and processing, samples that did not meet the criteria were excluded, leaving 5,259 samples. Using BMI \geq 25 as the threshold for overweight classification, the samples were divided into an overweight group and a control group. Further stratified screening of the samples resulted in the final inclusion of 3,606 samples, with 1,563 in the normal group and 2,043 in the overweight group, as illustrated in Figure 1 and detailed in Supplementary Table S1.

The study included a total of 4,419 bacterial species. Analysis of the gut microbiota in the two sample groups revealed that the relative abundance and frequency of 705 bacterial species differed significantly between the groups (p < 0.01). After applying Bonferroni correction, 283 bacterial species remained significantly different (adjusted *p*-value <0.01). These bacterial species were then ranked by frequency of occurrence. Considering model complexity and computational power, the top 40 bacterial species were selected as features for constructing the ML model (Table 1). Additionally, to enhance prediction accuracy, gender and age were included as feature variables, given their potential influence on the gut microbiome composition (Hales et al., 2018; Ge et al., 2024).

Differences in gut microbiota diversity between overweight and control groups

The analysis revealed significant differences in gut microbiota diversity between the overweight and control groups. Figure 2A presents a stacked bar chart illustrating the changes in microbial composition, emphasizing the substantial impact of overweight status on gut microbiota diversity and composition. Figure 2B displays boxplots comparing the Shannon index and Chao1 index, showing that the control group exhibited a wider range and higher median values for both indices. This further reinforces the observation of reduced microbial diversity in individuals with overweight status.



Specifically, the Shannon index, which reflects the richness and evenness of microbial communities, was significantly lower in the overweight group compared to the control group. Similarly, the Chao1 index, an indicator of species richness, also demonstrated a significant decrease in the overweight group, indicating a shift in microbial diversity associated with overweight status. Figure 2C presents a heatmap generated from the relative abundance of microbial taxa, clearly illustrating the clustering of samples, with distinct groupings observed between the overweight and control groups. Specific taxa showed significant differences in abundance, supporting the findings from the diversity indices.

XGBoost outperforms in overweight model classification

Using BMI classification as the response variable and incorporating the 40 bacterial species listed in Table 1, along with gender and age as feature variables, we constructed prediction models using XGBoost, logistic regression, decision tree, and support vector machine (SVM). The results represent the average performance metrics (accuracy, precision, recall, F_1 -score, and AUC) obtained from 5-fold cross-validation on the validation data. Among these models, the XGBoost model achieved the highest overall performance (Figure 3A), demonstrating its suitability for this task.

Subsequently, we used GridSearchCV to fine-tune the parameters of the XGBoost model. The performance metrics and ROC curve of the optimized model are shown in Figures 3B,C. The fine-tuned model achieved an accuracy of 0.8144, a precision of 0.8191, a recall of 0.8481, and an F_1 -score of 0.8333. Additionally, the AUC was 0.90, indicating that the model performs well and is suitable for further research.

Model global visualization

The importance matrix of the XGBoost model, shown in Figure 4, highlights the top 10 most significant variables contributing to the model. These variables are host age, *Akkermansia muciniphila*, *Alistipes putredinis*, sex, *Alistipes finegoldii*, *Blautia obeum*, *Barnesiella viscericola*, *Alistipes onderdonkii*, *B. pseudocatenulatum*, and *Anaerotruncus colihominis*.

By calculating the Shapley values for each feature, we gain a clear understanding of how each feature influences the model's predictions. This is crucial for revealing feature importance and the predictive mechanisms of the model (Ning et al., 2022). To identify the features with the most significant impact on the predictive model, we plotted the SHAP summary plot for the XGBoost model (Figure 5). Higher SHAP values for a feature indicate a greater likelihood of being overweight.

Our analysis revealed that features such as *Akkermansia muciniphila*, *Barnesiella viscericola*, *Alistipes onderdonkii*, *B. pseudocatenulatum*, and *Anaerotruncus colihominis* have negative SHAP values, suggesting that their abundance is inversely related to BMI. In contrast, *Odoribacter splanchnicus* exhibits a positive impact on BMI. While features like age and sex significantly contribute to the model's predictions, their biological implications are less clear in terms of explanatory power.

Interpretation of personalized predictions

SHAP values illustrate the contribution of each feature to the final prediction, providing a clear explanation of the model's predictions for individual patients. As shown in Figure 6, we selected an overweight sample to demonstrate the model's interpretability. In this case, age had the highest positive contribution to BMI, with a SHAP value of 0.62. Conversely, *B. pseudocatenulatum, Roseburia hominis*, and *Akkermansia muciniphila* had negative contributions to BMI, with SHAP values of -0.58, -6.1, and -0.92, respectively.

Bifidobacterium pseudocatenulatum inhibits fat deposition in *Caenorhabditis elegans*

This study employed machine learning (ML) to predict several bacterial strains associated with BMI. To validate the potential functions of these strains, we examined the effect of *B. pseudocatenulatum* on fat reduction using *Caenorhabditis elegans* as a model, with *Escherichia coli* OP50 as the blank control. Four strains of *B. pseudocatenulatum* (JXL-01, JXL-02, JXL-03, and JXL-05) were selected based on their availability and prior verification of their fat-reducing properties, which were identified through our ML

TABLE 1 Top 40 target bacteria.

Species	Fisher <i>p</i> -value	Adjusted Fisher <i>p</i> -value	<i>p</i> -value	Adjusted <i>p</i> -value
Blautia obeum	$7.07 imes 10^{-26}$	3.13×10^{-22}	$8.45 imes 10^{-27}$	$3.73 imes 10^{-23}$
Alistipes putredinis	2.68×10^{-22}	$1.19 imes 10^{-18}$	$1.40 imes 10^{-18}$	$6.17 imes 10^{-15}$
Alistipes shahii	$3.97 imes 10^{-22}$	1.75×10^{-18}	1.98×10^{-11}	$8.76 imes 10^{-8}$
Dorea formicigenerans	1.08×10^{-25}	4.76×10^{-22}	2.88×10^{-15}	1.27×10^{-11}
Parabacteroides merdae	$8.87 imes 10^{-35}$	3.92×10^{-31}	3.52×10^{-15}	1.56×10^{-11}
Roseburia hominis	$8.94 imes 10^{-13}$	3.95×10^{-9}	$2.30 imes 10^{-10}$	1.02×10^{-6}
Alistipes onderdonkii	$7.97 imes 10^{-12}$	$3.52 imes 10^{-8}$	4.09×10^{-15}	1.81×10^{-11}
Akkermansia muciniphila	1.12×10^{-38}	4.96×10^{-35}	3.06×10^{-46}	$1.35 imes 10^{-42}$
Eubacterium ventriosum	1.62×10^{-15}	7.16×10^{-12}	$1.34 imes 10^{-8}$	5.92×10^{-5}
Alistipes finegoldii	$2.05 imes 10^{-6}$	0.009046201	$8.88 imes 10^{-8}$	0.000392558
Clostridium leptum	$2.10 imes 10^{-26}$	9.27×10^{-23}	2.20×10^{-32}	$9.71 imes 10^{-29}$
Eubacterium ramulus	2.87×10^{-9}	1.27×10^{-5}	9.87×10^{-12}	$4.36 imes 10^{-8}$
Bacteroides massiliensis	1.35×10^{-21}	5.96×10^{-18}	5.09×10^{-13}	2.25×10^{-9}
Odoribacter splanchnicus	$5.95 imes 10^{-14}$	2.63×10^{-10}	2.04×10^{-8}	9.00×10^{-5}
Bilophila wadsworthia	1.49×10^{-35}	6.59×10^{-32}	$2.85 imes 10^{-27}$	1.26×10^{-23}
Clostridium bolteae	$2.19\times10^{_{-16}}$	9.68×10^{-13}	$5.33 imes 10^{-17}$	$2.35 imes 10^{-13}$
Streptococcus thermophilus	$2.06 imes 10^{-10}$	$9.10 imes 10^{-7}$	1.45×10^{-8}	6.42×10^{-5}
Bacteroides intestinalis	1.38×10^{-25}	$6.10 imes 10^{-22}$	$1.76 imes 10^{-19}$	$7.79 imes 10^{-16}$
Ruminococcus callidus	$1.42 imes 10^{-26}$	6.26×10^{-23}	$8.77 imes 10^{-19}$	$3.87 imes 10^{-15}$
Clostridium symbiosum	1.51×10^{-24}	6.67×10^{-21}	$4.33 imes 10^{-21}$	1.91×10^{-17}
Anaerotruncus colihominis	1.32×10^{-29}	5.81×10^{-26}	$2.48 imes 10^{-42}$	1.09×10^{-38}
Holdemania filiformis	1.14×10^{-22}	5.03×10^{-19}	2.30×10^{-23}	1.01×10^{-19}
Bacteroides eggerthii	$3.67 imes 10^{-14}$	1.62×10^{-10}	$6.49 imes 10^{-15}$	2.87×10^{-11}
Alistipes indistinctus	$4.51 imes 10^{-18}$	$1.99 imes 10^{-14}$	4.24×10^{-15}	1.88×10^{-11}
Clostridium indolis	1.44×10^{-22}	$6.36 imes 10^{-19}$	6.01 × 10 ⁻²³	2.65×10^{-19}
Dscillibacter valericigenes	$1.07 imes 10^{-20}$	4.71×10^{-17}	1.07×10^{-27}	$4.74 imes 10^{-24}$
Bacteroides nordii	4.91×10^{-7}	0.002171386	1.51×10^{-6}	0.006665991
Bacteroides coprocola	2.66×10^{-17}	1.18×10^{-13}	3.41×10^{-9}	1.51×10^{-5}
Ruminiclostridium thermocellum	$1.33 imes 10^{-20}$	5.87×10^{-17}	$9.64 imes 10^{-29}$	4.26×10^{-25}
Streptococcus mitis	1.01×10^{-16}	$4.45 imes 10^{-13}$	$5.40 imes 10^{-18}$	$2.39 imes 10^{-14}$
Sporobacter termitidis	6.89×10^{-23}	3.04×10^{-19}	1.66×10^{-31}	$7.35 imes 10^{-28}$
Coprococcus eutactus	$4.36 imes 10^{-16}$	1.93×10^{-12}	3.67×10^{-16}	1.62×10^{-12}
Clostridium saccharolyticum	$6.32 imes 10^{-20}$	2.79×10^{-16}	8.26×10^{-21}	3.65×10^{-17}
Eubacterium desmolans	2.27×10^{-19}	1.00×10^{-15}	1.30×10^{-19}	5.77×10^{-16}
Clostridium spiroforme	$3.24 imes 10^{-18}$	$1.43 imes 10^{-14}$	1.71×10^{-21}	$7.56 imes 10^{-18}$
Blautia glucerasea	$3.58 imes 10^{-19}$	1.58×10^{-15}	$9.11 imes 10^{-20}$	$4.03 imes 10^{-16}$
Barnesiella viscericola	$7.60 imes 10^{-32}$	3.36×10^{-28}	$7.73 imes 10^{-41}$	3.41×10^{-37}
Bifidobacterium pseudocatenulatum	$1.82 imes 10^{-14}$	8.03×10^{-11}	$1.51 imes 10^{-12}$	6.67×10^{-9}
Ruminococcus albus	$2.13 imes 10^{-20}$	9.42×10^{-17}	$2.33 imes 10^{-24}$	$1.03 imes 10^{-20}$
Clostridium methylpentosum	2.87×10^{-21}	1.27×10^{-17}	1.60×10^{-20}	7.09×10^{-17}

analysis of bacterial strains associated with BMI. Additionally, these strains have been implicated in obesity-related studies (Cano et al., 2013), providing further justification for their selection. These initial

findings allowed us to identify the most effective strains for further cell experiments, and lipid accumulation in *C. elegans* was compared after feeding with each of these four *B. pseudocatenulatum* strains.





Results showed that, compared to the *E. coli* OP50 group, fat content in nematodes fed with the four strains of *B. pseudocatenulatum* was significantly reduced (Figure 7A). Further analysis of red fluorescence intensity, which indicates fat content, revealed that the strains JXL-01, JXL-02, JXL-03, and JXL-05 resulted in significant reductions in fat fluorescence intensity by 39.25, 24.95, 38.6, and 19.29%, respectively (Figure 7B). These findings suggest that *B. pseudocatenulatum* can significantly reduce fat deposition in nematodes, thereby influencing fat metabolism.

Bifidobacterium pseudocatenulatum inhibits adipogenic differentiation

Based on the results from the *C. elegans* experiment, we selected the *B. pseudocatenulatum* JXL-01 strain for further investigation into its

effect on adipogenic differentiation using mouse mesenchymal stem cells (C3H10 cells). The cells were divided into two groups: a control group and a B. pseudocatenulatum intervention group (B.p). To assess the impact of B. pseudocatenulatum metabolites on cell viability, a CCK8 assay was first performed. We chose to co-culture C3H10 cells with 10% of the bacterial metabolites (Figure 8A). To evaluate the effects on adipogenic differentiation, we used Oil Red O staining to visualize lipid accumulation. The results showed that lipid droplets were significantly reduced in the B.p group compared to the control group (Figure 8B). Quantitative analysis of the lipid content confirmed the reduction in lipid droplets in the B.p group (Figure 8C). Furthermore, we assessed the expression of key adipogenic transcription factors, including PPARy and FABP4, which are upregulated during adipocyte differentiation. The mRNA levels of PPARy and FABP4 were significantly inhibited in the B.p group (Figure 8D-E), suggesting that B. pseudocatenulatum can significantly reduce adipogenic differentiation. These findings

Host age	+0.65	
Akkermansia muciniphila	+0.34	
Alistipes putredinis	+0.31	
Sex	+0.3	
Alistipes finegoldii	+0.24	
Blautia obeum	+0.23	
Barnesiella viscericola	+0.22	
Alistipes onderdonkii	+0.21	
Bifidobacterium pseudocatenulatum	+0.21	
Anaerotruncus colihominis	+0.21	
Parabacteroides merdae	+0.2	
Odoribacter splanchnicus	+0.16	
Alistipes shahii	+0.16	
Bacteroides massiliensis	+0.15	
Streptococcus thermophilus	+0.15	
Bacteroides eggerthii	+0.15	
Roseburia hominis	+0.14	
Eubacterium ramulus	+0.14	
Sporobacter termitidis	+0.13	
Clostridium symbiosum	+0.13	
Coprococcus eutactus	+0.13	
Alistipes indistinctus	+0.13	
Bacteroides intestinalis	+0.12	
Bacteroides nordii	+0.12	
Blautia glucerasea	+0.12	
Ruminococcus callidus	+0.11	
Clostridium bolteae	+0.11	
Eubacterium ventriosum	+0.11	
Dorea formicigenerans	+0.1	
Oscillibacter valericigenes	+0.1	
Clostridium indolis	+0.1	
Ruminococcus albus	+0.1	
Clostridium leptum	+0.09	
Bilophila wadsworthia	+0.09	
Ruminiclostridium thermocellum	+0.09	
Bacteroides coprocola	+0.08	
Eubacterium desmolans	+0.07	
Holdemania filiformis	+0.07	
Clostridium spiroforme	+0.06	
Clostridium methylpentosum	+0.05	
Streptococcus mitis		
Clostridium saccharolyticum		
(0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7	
	mean(SHAP value)	

FIGURE 4

Importance matrix plot of the XGboost model. This importance matrix plot depicts the importance of each covariate in the development of the final predictive model.

demonstrate that B. pseudocatenulatum JXL-01 significantly influences fat deposition and adipogenic differentiation in C3H10 cells, promoting a reduction in fat accumulation.

Discussion

Obesity represents a significant public health challenge (Artasensi et al., 2023). The role of the microbiome in health and disease is increasingly recognized, yet the complex and dynamic interactions between host-microbiome and microbe-microbe interactions complicate the identification of beneficial versus harmful bacteria or bacterial combinations. While many studies have reported correlations between the microbiome and health (Van Hul and Cani, 2023), large-scale data studies on obesity-related microbiomes utilizing ML are lacking.

In this study, we predicted the distribution of gut microbiota between overweight (BMI ≥25) and normal weight (BMI <25) groups, employing four ML algorithms for classification. Among these, the XGBoost model demonstrated superior performance, achieving an AUC of 0.90. Furthermore, through the use of SHAP values and SHAP plots, we illustrated that ML methods can elucidate the key features of the gut microbiota associated with overweight populations. This approach facilitated the visual interpretation of feature importance, offering a clear understanding of the critical features identified by the XGBoost model.

However, it is important to note a limitation in our study design. Individuals with obesity (BMI \geq 30) were included in the overweight group, which was defined as BMI ≥25. This broad definition may mask specific microbiota differences between overweight and obese individuals, potentially limiting the granularity of our findings. Future research should consider analyzing subgroups within the BMI \geq 25 category to better delineate microbiota changes associated with varying degrees of overweight and obesity.

Overall, this study makes several important contributions. We employed XGBoost to develop a ML classification model for identifying overweight individuals and confirmed the effectiveness and reliability of XGBoost in this context. Notably, our analysis revealed that the relative abundances of A. muciniphila, B. viscericola, A. onderdonkii, B. pseudocatenulatum, and A. colihominis are negatively correlated with increased BMI.

Among these gut bacteria, a deficiency or reduced abundance of A. muciniphila has been associated with various diseases, including obesity, diabetes, hepatic steatosis, and inflammation, suggesting its potential as a probiotic for improving fat accumulation and treating obesity (Cani et al., 2022). B. viscericola has been linked to improved outcomes in obesity and hepatic steatosis in animal studies, with increased abundance of Barnesiella species showing benefits (Rodriguez et al., 2020). Alistipes is a relatively new genus, and human studies have found that A. onderdonkii is associated with weight loss following fecal microbiota transplantation and is negatively correlated with waist circumference (Zhang et al., 2022; Qin et al., 2021). Although research on B. pseudocatenulatum is limited, available studies suggest that supplementation with this bacterium can improve obesity-related bone metabolism disorders and regulate inflammation associated with obesity (Fernandez-Murga et al., 2020; Sanchis-Chorda et al., 2019; Moya-Perez et al., 2015). A. colihominis, a bacterium capable of producing short-chain fatty acids, may play a role in improving glucose tolerance (Yao et al., 2020). These findings underscore the potential of specific gut



SHAP summary plot of the XGBoost model. Each dot in the plot represents a feature attribution value for a patient, with one dot per feature per patient. Dots are colored based on the feature values for each patient, with red indicating higher feature values and blue indicating lower feature values. The vertical accumulation of dots illustrates the density of feature attributions.

bacteria in managing and understanding obesity, highlighting the value of microbiome research and ML models in identifying key bacterial species linked to health outcomes.

However, it is important to note that training performance metrics, such as accuracy and precision, do not fully reflect a model's performance in real-world applications. These metrics may be overly optimistic, particularly for high-capacity models like XGBoost, which can fit well to training data but may not generalize effectively to unseen data. To obtain a more reliable evaluation of our model's performance, we relied on cross-validation results, which provide a more robust assessment of the model's generalization ability.



Based on the findings mentioned, we selected *B. pseudocatenulatum* for further validation of its fat-reducing effects in nematodes and cell models. Our research results indicate that all four strains of *B. pseudocatenulatum* improved lipid deposition in

Caenorhabditis elegans. Additionally, our studies revealed that the metabolites of *B. pseudocatenulatum* can inhibit the adipogenic differentiation of mesenchymal stem cells. This research not only represents a significant advancement in the application of ML but



FIGURE 7

Effect of *B. pseudocatenulatum* on fat metabolism in nematodes. (A) Oil Red O staining of Caenorhabditis elegans *C. elegans* to visualize lipid accumulation. (B) Quantitative analysis of Oil Red O staining, showing the degree of lipid deposition in the nematodes.



also provides novel insights into the development of probiotics like *B. pseudocatenulatum* for obesity management.

The gut microbiota is believed to play a significant role in the pathophysiology of obesity and is considered a potential therapeutic target. Bacterial metabolites, including short-chain fatty acids (SCFAs), bile acids, and trimethylamine N-oxide (TMAO), interact with specific receptors such as peroxisome proliferator-activated receptors α (PPAR α) and γ (PPAR γ), aryl hydrocarbon receptor

(AhR), and G-protein-coupled receptors (GPR41, GPR43, GPR119, TGR5), thereby influencing host metabolism (de Vos et al., 2022; Bai et al., 2020). This underscores the need for further research to develop probiotic products and to better understand the mechanisms of microbe-host interactions.

Conclusion

The gut microbiota is closely associated with overweight and obesity. By employing ML methods, we developed a classification prediction model to identify and screen gut microbiota related to overweight. The integration of ML and SHAP (SHapley Additive exPlanations) offers clear explanations for individualized risk predictions, allowing researchers to intuitively understand the impact of key features in the model. Our analysis identified several key bacteria negatively correlated with obesity, including *Alistipes onderdonkii*, *Bacteroides massiliensis*, *Haemophilus parainfluenzae*, and *B. pseudocatenulatum*.

Further *in vivo* and *in vitro* experiments have demonstrated that *B. pseudocatenulatum* may influence fat deposition in nematodes and adipocyte differentiation. These findings suggest that it could be a promising intervention for weight loss. Overall, our study represents a significant and necessary advancement toward utilizing gut microbiota modulation or specific active compounds for weight reduction.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

Ethical approval was not required for the studies involving humans because this article contains human participants collected from several studies performed by previous studies. All participants gave informed consent in all the corresponding original studies, as described in the methods. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from the data used in this study is freely available for download in the GMrepo database, https:// gmrepo.humangut.info. Written informed consent to participate in this study was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and the institutional requirements. Ethical approval was not required for the studies on animals in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.

Author contributions

HW: Conceptualization, Methodology, Software, Validation, Writing – original draft. YL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft. YJ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft. XL: Data curation, Methodology, Validation, Writing – review & editing. SW: Methodology, Software, Validation, Writing – original draft. CZ: Formal analysis, Methodology, Software, Writing – original draft. XY: Data curation, Methodology, Writing – original draft. BC: Funding acquisition, Resources, Supervision, Writing – review & editing. JY: Investigation, Project administration, Resources, Supervision, Writing – review & editing. JQ: Funding acquisition, Resources, Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the National Key Research and Development Program of China (2023YFC3402401), National Natural Science Foundation of China (82074253 and 82274299), Natural Science Foundation of Tianjin (23JCYBJC00880), and Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-032A).

Acknowledgments

The data analyzed in this study was provided by the GMrepo database. We gratefully acknowledge their contributing studies and the participants in the corresponding studies without whom this effort would not be possible. We also extend our gratitude to the Zhu Endong research group from Tianjin Medical University for their contribution of the C3H10 cells used in our study.

Conflict of interest

YJ was employed by Yidu Cloud (Beijing) Technology Co., Ltd. All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2024.1488656/ full#supplementary-material

10.3389/fmicb.2024.1488656

References

Artasensi, A., Mazzolari, A., Pedretti, A., Vistoli, G., and Fumagalli, L. (2023). Obesity and type 2 diabetes: adiposopathy as a triggering factor and therapeutic options. *Molecules* 28:3094. doi: 10.3390/molecules28073094

Backhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., et al. (2004). The gut microbiota as an environmental factor that regulates fat storage. *Proc. Natl. Acad. Sci. U.S.A.* 101, 15718–15723. doi: 10.1073/pnas.0407076101

Bai, L., Gao, M., Cheng, X., Kang, G., Cao, X., and Huang, H. (2020). Engineered butyrate-producing bacteria prevents high fat diet-induced obesity in mice. *Microb. Cell Fact.* 19:94. doi: 10.1186/s12934-020-01350-z

Cani, P. D., Depommier, C., Derrien, M., Everard, A., and de Vos, W. M. (2022). *Akkermansia muciniphila*: paradigm for next-generation beneficial microorganisms. *Nat. Rev. Gastroenterol. Hepatol.* 19, 625–637. doi: 10.1038/s41575-022-00631-9

Cano, P. G., Santacruz, A., Trejo, F. M., and Sanz, Y. (2013). *Bifidobacterium* CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice. *Obesity* 21, 2310–2321. doi: 10.1002/oby.20330

Carvalho, B. M., Guadagnini, D., Tsukumo, D., Schenka, A. A., Latuf-Filho, P., Vassallo, J., et al. (2012). Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. *Diabetologia* 55, 2823–2834. doi: 10.1007/s00125-012-2648-4

Cho, I., Yamanishi, S., Cox, L., Methe, B. A., Zavadil, J., Li, K., et al. (2012). Antibiotics in early life alter the murine colonic microbiome and adiposity. *Nature* 488, 621–626. doi: 10.1038/nature11400

Cox, L. M., Yamanishi, S., Sohn, J., Alekseyenko, A. V., Leung, J. M., Cho, I., et al. (2014). Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. *Cell* 158, 705–721. doi: 10.1016/j.cell.2014.05.052

Dao, M. C., Everard, A., Aron-Wisnewsky, J., Sokolovska, N., Prifti, E., Verger, E. O., et al. (2016). *Akkermansia muciniphila* and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut* 65, 426–436. doi: 10.1136/gutjnl-2014-308778

de Vos, W. M., Tilg, H., Van Hul, M., and Cani, P. D. (2022). Gut microbiome and health: mechanistic insights. *Gut* 71, 1020–1032. doi: 10.1136/gutjnl-2021-326789

Deo, R. C. (2015). Machine learning in medicine. *Circulation* 132, 1920–1930. doi: 10.1161/CIRCULATIONAHA.115.001593

Fernandez-Murga, M. L., Olivares, M., and Sanz, Y. (2020). *Bifidobacterium pseudocatenulatum* CECT 7765 reverses the adverse effects of diet-induced obesity through the gut-bone axis. *Bone* 141:115580. doi: 10.1016/j.bone.2020.115580

Ge, Y. Z., Liu, T., Deng, L., Zhang, Q., Liu, C. A., Ruan, G. T., et al. (2024). The agerelated obesity paradigm: results from two large prospective cohort studies. *J. Cachexia. Sarcopenia Muscle* 15, 442–452. doi: 10.1002/jcsm.13415

Hales, C. M., Fryar, C. D., Carroll, M. D., Freedman, D. S., and Ogden, C. L. (2018). Trends in obesity and severe obesity prevalence in us youth and adults by sex and age, 2007–2008 to 2015–2016. *JAMA* 319, 1723–1725. doi: 10.1001/jama.2018.3060

Heindel, J. J., Lustig, R. H., Howard, S., and Corkey, B. E. (2024). Obesogens: a unifying theory for the global rise in obesity. *Int. J. Obes.* 48, 449–460. doi: 10.1038/ s41366-024-01460-3

Koutnikova, H., Genser, B., Monteiro-Sepulveda, M., Faurie, J. M., Rizkalla, S., Schrezenmeir, J., et al. (2019). Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. *BMJ Open* 9:e17995:e017995. doi: 10.1136/ bmjopen-2017-017995

Laine, C., and Wee, C. C. (2023). Overweight and obesity: current clinical challenges. *Ann. Intern. Med.* 176, 699–700. doi: 10.7326/M23-0628

Li, X., Zhao, Y., Zhang, D., Kuang, L., Huang, H., Chen, W., et al. (2023). Development of an interpretable machine learning model associated with heavy metals' exposure to

identify coronary heart disease among us adults via SHAP: findings of the us NHANES from 2003 to 2018. Chemosphere 311:137039. doi: 10.1016/j.chemosphere.2022.137039

Liang, Y., Dou, S., Zhao, G., Shen, J., Fu, G., Fu, L., et al. (2023). Prediction of BMI traits in the Chinese population based on the gut metagenome. *Microb. Cell Fact.* 22:250. doi: 10.1186/s12934-023-02255-3

Moya-Perez, A., Neef, A., and Sanz, Y. (2015). *Bifidobacterium pseudocatenulatum* CECT 7765 reduces obesity-associated inflammation by restoring the lymphocytemacrophage balance and gut microbiota structure in high-fat diet-fed mice. *PLoS One* 10:e126976. doi: 10.1371/journal.pone.0126976

Ning, Y., Ong, M., Chakraborty, B., Goldstein, B. A., Ting, D., Vaughan, R., et al. (2022). Shapley variable importance cloud for interpretable machine learning. *Patterns* 3:100452. doi: 10.1016/j.patter.2022.100452

Qin, Q., Yan, S., Yang, Y., Chen, J., Li, T., Gao, X., et al. (2021). A metagenome-wide association study of the gut microbiome and metabolic syndrome. *Front. Microbiol.* 12:682721. doi: 10.3389/fmicb.2021.682721

Qiu, X., Wu, Q., Li, W., Tang, K., and Zhang, J. (2022). Effects of lactobacillus supplementation on glycemic and lipid indices in overweight or obese adults: a systematic review and meta-analysis. *Clin. Nutr.* 41, 1787–1797. doi: 10.1016/j. clnu.2022.06.030

Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., et al. (2023). Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. *Lancet Gastroenterol. Hepatol.* 8, 20–30. doi: 10.1016/S2468-1253(22)00317-X

Rodriguez, J., Hiel, S., Neyrinck, A. M., Le Roy, T., Potgens, S. A., Leyrolle, Q., et al. (2020). Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients. *Gut* 69, 1975–1987. doi: 10.1136/gutjnl-2019-319726

Safaei, M., Sundararajan, E. A., Driss, M., Boulila, W., and Shapi'I, A. (2021). A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. *Comput. Biol. Med.* 136:104754. doi: 10.1016/j.compbiomed.2021.104754

Sanchis-Chorda, J., Del, P. E., Carrasco-Luna, J., Benitez-Paez, A., Sanz, Y., and Codoner-Franch, P. (2019). *Bifidobacterium pseudocatenulatum* cect 7765 supplementation improves inflammatory status in insulin-resistant obese children. *Eur. J. Nutr.* 58, 2789–2800. doi: 10.1007/s00394-018-1828-5

Song, W., Wu, F., Yan, Y., Li, Y., Wang, Q., Hu, X., et al. (2023). Gut microbiota landscape and potential biomarker identification in female patients with systemic lupus erythematosus using machine learning. *Front. Cell. Infect. Microbiol.* 13:1289124. doi: 10.3389/fcimb.2023.1289124

Tome-Castro, X. M., Rodriguez-Arrastia, M., Cardona, D., Rueda-Ruzafa, L., Molina-Torres, G., and Roman, P. (2021). Probiotics as a therapeutic strategy in obesity and overweight: a systematic review. *Benef. Microbes* 12, 5–15. doi: 10.3920/BM2020.0111

Tsai, A. G., and Bessesen, D. H. (2019). Obesity: Ann. Intern. Med. 170:ITC33-48. doi: 10.7326/AITC201903050

Van Hul, M., and Cani, P. D. (2023). The gut microbiota in obesity and weight management: microbes as friends or foe? *Nat. Rev. Endocrinol.* 19, 258–271. doi: 10.1038/s41574-022-00794-0

Velazquez, A., and Apovian, C. M. (2018). Updates on obesity pharmacotherapy. Ann. N. Y. Acad. Sci. 1411, 106–119. doi: 10.1111/nyas.13542

Yao, Y., Yan, L., Chen, H., Wu, N., Wang, W., and Wang, D. (2020). *Cyclocarya paliurus* polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids. *Phytomedicine* 77:153268. doi: 10.1016/j.phymed.2020.153268

Zhang, F., Zuo, T., Wan, Y., Xu, Z., Cheung, C., Li, A. Y., et al. (2022). Multi-omic analyses identify mucosa bacteria and fecal metabolites associated with weight loss after fecal microbiota transplantation. *Innovation* 3:100304. doi: 10.1016/j.xinn.2022.100304